A High Point-based company developing drugs to treat Alzheimer’s disease and diabetes reported a small-than-expected loss during the second quarter, according to a filing Wednesday with the Securities and Exchange Commission.

VTV Therapeutics Inc. reported a net loss of $3.9 million, or 41 cents per share, during the second quarter, better than the loss of $4.5 million, or 47 cents per share, in the same quarter a year ago, and better than the projected loss of 43 cents.

Revenue was $13,000, below expectations of revenue of $50,000. It had $182,000 in revenue in the second quarter of 2016.

““With positive progress in our lead Alzheimer’s and diabetes programs, vTv is pleased to showcase another productive quarter,” said Chief Executive Officer Steve Holcombe in a statement.

The company’s shares fell 10 cents to $4.39 on Wednesday. The earnings were announced after the market closed.

At the American Diabetes Association meeting in June, the company presented updates from its Phase 2 clinical study of its diabetes drug that may expand the treatment options for patients with Type 2 diabetes.

VTV also completed enrollment of Part B of its Phase 3 study of its Alzheimer’s drug, and expects data from Part A early next year.

“If positive, those data position vTv Therapeutics to be the first biopharmaceutical company to bring an investigational therapy before the FDA that could potentially delay progression of clinical symptoms of Alzheimer’s disease,” said Holcombe.

Research and development expenses in the second quarter were $9.6 million, down 20.8 percent from R&D expenses of $12.1 million in the second quarter of 2016.